Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02487485 · ClinicalTrials.gov registry record · Phase 2
Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT02487485 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 23 participants.
The verdict
NCT02487485, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The aim of the study is to provide insight into the impact of the immunosuppressant drug sirolimus, on the antidepressant effects of the prototypal rapid-acting antidepressant medication, ketamine.
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02487485
The ClinicalTrials.gov registry entry for NCT02487485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02487485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02487485 about?
NCT02487485 is a clinical study titled "Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects". The aim of the study is to provide insight into the impact of the immunosuppressant drug sirolimus, on the antidepressant effects of the prototypal rapid-acting antidepressant medication, ketamine.
What is the current status of trial NCT02487485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2016-03. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02487485?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), sirolimus (DRUG).
Who is sponsoring clinical trial NCT02487485?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.